Fate Therapeutics Inc (NASDAQ: FATE) kicked off on Monday, down -2.25% from the previous trading day, before settling in for the closing price of $5.77. Over the past 52 weeks, FATE has traded in a range of $1.63-$8.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 87.14% over the last five years. While this was happening, its average annual earnings per share was recorded -17.51%. With a float of $86.74 million, this company’s outstanding shares have now reached $98.63 million.
The firm has a total of 181 workers. Let’s measure their productivity.
Fate Therapeutics Inc (FATE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 12.59%, while institutional ownership is 103.93%. The most recent insider transaction that took place on Mar 04 ’24, was worth 19,013. In this transaction Chief Financial Officer of this company sold 2,447 shares at a rate of $7.77, taking the stock ownership to the 101,479 shares. Before that another transaction happened on Jan 29 ’24, when Company’s Chief Financial Officer sold 1,849 for $5.00, making the entire transaction worth $9,245. This insider now owns 103,926 shares in total.
Fate Therapeutics Inc (FATE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -17.51% per share during the next fiscal year.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Take a look at Fate Therapeutics Inc’s (FATE) current performance indicators. Last quarter, stock had a quick ratio of 8.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.63, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Analysing the last 5-days average volume posted by the [Fate Therapeutics Inc, FATE], we can find that recorded value of 2.08 million was lower than the volume posted last year of 2.8 million. As of the previous 9 days, the stock’s Stochastic %D was 7.41%. Additionally, its Average True Range was 0.53.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 52.60%, which indicates a significant increase from 11.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.94% in the past 14 days, which was lower than the 92.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.94, while its 200-day Moving Average is $4.08. Now, the first resistance to watch is $5.93. This is followed by the second major resistance level at $6.23. The third major resistance level sits at $6.50. If the price goes on to break the first support level at $5.37, it is likely to go to the next support level at $5.10. Now, if the price goes above the second support level, the third support stands at $4.80.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
The company with the Market Capitalisation of 559.71 million has total of 99,238K Shares Outstanding. Its annual sales at the moment are 63,530 K in contrast with the sum of -160,930 K annual income. Company’s last quarter sales were recorded 1,680 K and last quarter income was -44,120 K.
